Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

We have 5 Other (prostate cancer) PhD Projects, Programmes & Scholarships

Discipline

Discipline

Medicine

Location

Location

All locations

Institution

Institution

All Institutions

PhD Type

PhD Type

All PhD Types

Funding

Funding

All Funding


Other (prostate cancer) PhD Projects, Programmes & Scholarships

We have 5 Other (prostate cancer) PhD Projects, Programmes & Scholarships

Identifying DNA methylation signatures of prostate cancer progression and mortality among patients with clinically confirmed, localised disease at baseline in a large prospective clinical trial

Rationale. Prostate Cancer (PCa) is a leading cause of male mortality, with 336,000 deaths worldwide each year (1). Although most PCa cases are indolent, slow-growing, and tend not to progress, a subset of PCa cases are more aggressive and will progress to metastases, treatment resistance and death. Read more

Estimating the global cancer burden due to low levels of physical activity

Rationale. Around 40% of all cancers are thought to be avoidable by modification of lifestyle factors. Obesity has been found to be a risk factor for several cancers and was estimated to have caused around 3.6% of all new cancers which occurred in 2012. Read more

Designing and evaluating novel nanotherapeutics to enhance the effectiveness of radiotherapy in the treatment of solid cancers.

One in two cancer patients will receive radiotherapy as part of their treatment. For patients with a localised cancer diagnosis effective radiotherapy represents the best chance of a curative outcome, however, is not without risk. Read more

Funded 9 Doctoral Candidate positions HORIZON-MSCA-Doctoral Network PROSTAMET

PROSTAMET is an immersive Doctoral Network (DN), that through the set-up of a unique comprehensive and modular translational pipeline aims to expose high achieving doctoral candidates to the complete research chain from cutting-edge molecular discovery all the way to innovative drug development, while focusing on the underexplored clinical potential of altered lipid metabolism in prostate cancer. Read more

Developing biodegradable long acting drug delivery systems for the treatment of chronic conditions

Non-adherence to treatment costs the NHS more than £500M each year. Adherence is especially important when treating patients with chronic conditions that require lifetime pharmacological treatment, such as schizophrenia, Parkinson’s disease, HIV and Alzheimer’s disease. Read more
  • 1

Filtering Results